IgE Antibody Composition for Cancer Treatment, King's College

Tue, 21 Apr 2026 13:30:11 +0000
Intellectual Property

USPTO granted Patent US12606617B2 to King's College London on April 21, 2026. The patent covers a pharmaceutical unit dosage composition comprising an IgE antibody in a dosage of less than 50 mg, intended for administration to mammalian subjects for treating cancer, specifically human ovarian cancers. The patent names four inventors and contains 21 claims.